Table 4.

Suggested entries in a supplemental antibody information sheet

Suggested entries	Available tools
1. Naming system
INN name and date	MedNet-INN
Trade name
National nomenclature (e.g. USAN)
2. Biological function
3. Development
Company
Source
Patent information	Espacenet patent search
4. Sequence information
Isotype/subtype
Germline alignment	IMGT/DomainGapAlign
Canonical structure class	Abysis
FR/CDR definition and lengths	Abysis
– Kabat
– Chothia
– IMGT	IMGT/DomainGapAlign
5. Protein/formulation properties
Binding properties
– Antigen specificity
– Affinity (KD)
– Binding rates $k_{\text{𝑜𝑛}}$, $k_{\text{𝑜𝑓𝑓}}$
Biophysical properties
– Thermal/chem. stability
– pI	Expasy/ProtParam
– Aggregation propensity (hydrophobic patches)
PTMs
– Glycosylation sites	NetNGlyc
– Terminal lysine modifications
Crystal structure
Expression system
6. Immunogenic risk assessment
In-silico analysis
– T cell epitopes	IEDB
– Humanness	Abysis
– Human string content (HSC)
in-vitro tests
– T-cell activation assays
Clinical
– Anti-drug antibody (ADA) titer
7. Other clinical data
Therapeutic area/ indication	IMGT/mAb-DB
EMA/FDA approval year
Prescription information	FDA drug database (drugs@FDA)
Biological half-life